Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI:10.1007/s13577-024-01083-w

Yan Wu, Dongfeng Chen, Yang Gao, Qinggang Xu, Yang Zhou, Zhong Ni, Manli Na

{"title":"Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?","authors":"Yan Wu, Dongfeng Chen, Yang Gao, Qinggang Xu, Yang Zhou, Zhong Ni, Manli Na","doi":"10.1007/s13577-024-01083-w","DOIUrl":null,"url":null,"abstract":"<p><p>Immunosuppressive regulatory cells (IRCs) play important roles in negatively regulating immune response, and are mainly divided into myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Large numbers of preclinical and clinical studies have shown that inhibition or reduction of IRCs could effectively elevate antitumor immune responses. However, several studies also reported that excessive inhibition of IRCs function is one of the main reasons causing the side effects of cancer immunotherapy. Therefore, the reasonable regulation of IRCs is crucial for improving the safety and efficiency of cancer immunotherapy. In this review, we summarised the recent research advances in the cancer immunotherapy by regulating the proportion of IRCs, and discussed the roles of IRCs in regulating tumour immune evasion and drug resistance to immunotherapies. Furthermore, we also discussed how to balance the potential opportunities and challenges of using IRCs to improve the safety of cancer immunotherapies.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s13577-024-01083-w","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Immunosuppressive regulatory cells (IRCs) play important roles in negatively regulating immune response, and are mainly divided into myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Large numbers of preclinical and clinical studies have shown that inhibition or reduction of IRCs could effectively elevate antitumor immune responses. However, several studies also reported that excessive inhibition of IRCs function is one of the main reasons causing the side effects of cancer immunotherapy. Therefore, the reasonable regulation of IRCs is crucial for improving the safety and efficiency of cancer immunotherapy. In this review, we summarised the recent research advances in the cancer immunotherapy by regulating the proportion of IRCs, and discussed the roles of IRCs in regulating tumour immune evasion and drug resistance to immunotherapies. Furthermore, we also discussed how to balance the potential opportunities and challenges of using IRCs to improve the safety of cancer immunotherapies.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症免疫疗法中的免疫抑制调节细胞：抑制还是调节？

免疫抑制调节细胞（IRCs）在负性调节免疫反应中发挥着重要作用，主要分为髓源性抑制细胞（MDSCs）和调节性T细胞（Tregs）。大量临床前和临床研究表明，抑制或减少 IRCs 可有效提高抗肿瘤免疫反应。然而，一些研究也指出，过度抑制 IRCs 的功能是导致癌症免疫疗法副作用的主要原因之一。因此，合理调控 IRCs 对提高癌症免疫疗法的安全性和有效性至关重要。在这篇综述中，我们总结了近年来通过调节 IRCs 比例进行癌症免疫治疗的研究进展，并讨论了 IRCs 在调节肿瘤免疫逃避和免疫疗法耐药性方面的作用。此外，我们还讨论了如何平衡使用IRCs的潜在机遇与挑战，以提高癌症免疫疗法的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊